JAMA N: Intravascular treatment for acute base artery astletic blockation.

Acute base arterial aclestation is a rare but catastrophic medical condition that accounts for all ischemic strokes and large vascular astleusces () at strokeDespite recent progress in acute stroke treatment, up to a high number of acute patients have died or remain severely disabledEarly reflux of acute stroke asthesion arteries has been shown to be associated with good functional prognosisResurgery treatment includes venous thrombolytic () intra-thrombotic mechanical thrombosis () angioplasting stent placement or combination therapyAlthough intravenous recombinant tissue-type lysozyme progenitor (; atepascotase) is still a first-line treatment drug for acute ischemic stroke () its benefits are limited in many ways such as narrow treatment time windows and low reflux rates in strokeA recent landmark intravascular treatment () trial has shown that it is a safe and effective treatment for patients with pre-circulatory diseaseHowever, it is uncertain whether acute patients will benefitRandomized clinical trials for ( ) and ( ) and ( ) have been initiated since thenAll of these studies of acute patients are designed to compare the benefits of standard medical ( ) plus and individual treatmentTrials were terminated early due to high cross rates and a decline in effective recruitment due to the loss of balance and the challenge of achieving inclusion targets because more and more stroke centers were reluctant to randomly assign patients to individual groups after the positive results of pre-circular stroke were publishedForward-looking data on acute scans remain scarceThe trial used to be a prospective registration study that recruited patients during the year; the trial did not find significant differences in functional prognosis between conventional treatmentHowever, since the study was completed years ago before the advent of modern technology and mechanical retransmission devices, its findings may not be applicable to current clinical practiceAlthough these studies have been assessed in many previous case series and meta-analyses, these studies have been limited in many ways, such as the one-arm nature of small sample sizes with different treatments that are outdatedThe results of the study published on Newbridge Hospital in China in January are designed to assess the safety and efficacy of modern plus or individual treatment in acute patients who expect to be closed during the period of closureNon-random cohort study is a forward-looking registration study involving a comprehensive stroke center in China that included patients with continuous diagnosis (acute, symptomatic, imaging)Acute patients within the blockist are expected to be divided into two groups: group and individual group The main endpoint is an improvement in the day rating A total of patients were evaluated for inclusion in the study One of the cases received a separate treatment Significantly improve sesame outcome of the day function (;) Also associated with a significantly higher proportion of days ( ; ) associated with a lower day mortality rate ( , ) , although it increases the risk of symptomatic cerebral hemorrhage ( The final authors believe that treatment within acute abstinle (estimated time) is associated with better functional outcomes and reduced mortality